Sai Life Sciences Achieves EcoVadis Platinum
Analysis based on 6 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026
The EcoVadis Platinum Rating for Sai Life Sciences is expected to positively impact its stock price and reputation, as investors increasingly prioritize companies with strong sustainability performance. This achievement could also attract more business from innovator pharma and biotech companies globally, who are looking for partners with robust environmental, social, and governance (ESG) credentials.
Sai Life Sciences, an India-headquartered contract research, development, and manufacturing organization, has achieved the EcoVadis Platinum Rating 2026. This places the company among the top 1% of companies globally for sustainability performance, with an overall score of 87/100. The recognition reflects sustained progress across environmental initiatives, labor and human rights practices, ethics, and sustainable procurement. Sai Life Sciences has implemented a 100% renewable-powered manufacturing site, reduced freshwater dependency, and invested in ecosystem restoration. The company has also strengthened its labor and human rights practices through SA8000 certification and alignment with living wage principles. Furthermore, Sai Life Sciences has enhanced governance with board-level oversight of sustainability and ethics and reinforced responsible procurement through supplier assessments and ISO 28000-certified supply chain security practices. This rating builds on previous commitments, including joining the Science Based Targets initiative (SBTi) in 2023 and becoming the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI) membership in 2020. Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the importance of sustainability as a defining measure of excellence in the industry.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard